Impact of the COVID-19 pandemic on population-based cancer registry

被引:23
作者
Soerjomataram, Isabelle [1 ]
Bardot, Aude [1 ]
Aitken, Joanne [2 ]
Pineros, Marion [1 ]
Znaor, Ariana [1 ]
Steliarova-Foucher, Eva [1 ]
Kohler, Betsy [3 ]
Bettio, Manola [4 ]
Matsuda, Tomohiro [5 ]
de Camargo Cancela, Marianna [6 ]
Mery, Les [1 ]
Bray, Freddie [1 ]
机构
[1] Int Agcy Res Canc, Canc Surveillance Branch, 150 Cours Albert Thomas, F-69008 Lyon, France
[2] Canc Council Queensland, Brisbane, Qld, Australia
[3] North Amer Assoc Cent Canc Registries, Springfield, IL USA
[4] European Commiss, Joint Res Ctr JRC, Ispra, Italy
[5] Natl Canc Ctr, Div Int Collaborat Res, Tokyo, Japan
[6] Brazilian Natl Canc Inst, Inst Nacl Canc, Div Surveillance, Rio De Janeiro, Brazil
关键词
COVID-19; pandemic; impact; international; population-based cancer registry; DIAGNOSIS; DELAYS;
D O I
10.1002/ijc.33792
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The COVID-19 pandemic has caused disruptions to national health systems and impacted health outcomes worldwide. However, the extent to which surveillance systems, such as population-based cancer registration, have been affected was not reported. Here we sought to evaluate the effect of the pandemic on registry operations across different areas and development levels worldwide. We investigated the impact of COVID-19 on three main areas of cancer registry operations: staffing, financing and data collection. An online survey was administered to 750 member registries of the International Association for Cancer Registries. Among 212 responding registries from 90 countries, 65.6% reported a disruption in operations, ranging between 45% in south-eastern Asia and 87% in the Latin America and Caribbean. Active data collection was disrupted more than case notifications or hybrid methods. In countries categorized with low Human Development Index (HDI), a greater number of registries reported a negative impact (81.3%) than in very high HDI countries (57.8%). This contrast was highest in term of impact on financing: 9/16 (56%) registries in low HDI countries reported a current or an expected decline in funding, compared to 7/108 (7%) in very high HDI countries. With many cancer registries worldwide reporting disruption to their operations during the early COVID-19 pandemic, urgent actions are needed to ensure their continuity. Governmental commitment to support future registry operations as an asset to disease control, alongside a move toward electronic reporting systems will help to ensure the sustainability of cancer surveillance worldwide.
引用
收藏
页码:273 / 278
页数:6
相关论文
共 21 条
  • [1] How will country-based mitigation measures influence the course of the COVID-19 epidemic?
    Anderson, Roy M.
    Heesterbeek, Hans
    Klinkenberg, Don
    Hollingsworth, T. Deirdre
    [J]. LANCET, 2020, 395 (10228) : 931 - 934
  • [2] [Anonymous], 2020, LANCET ONCOL, V21, P603, DOI 10.1016/S1470-2045(20)30243-6
  • [3] BCR, 2020, STRONG DECL NEW CANC
  • [4] Bray F., 2014, Planning and developing population-based cancer registration in low-and middle-income settings
  • [5] Cancer diagnostic rates during the 2020 'lockdown', due to COVID-19 pandemic, compared with the 2018-2019: an audit study from cellular pathology
    De Vincentiis, Ludovica
    Carr, Richard A.
    Mariani, Maria Paola
    Ferrara, Gerardo
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2021, 74 (03) : 187 - 189
  • [6] The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands
    Dinmohamed, Avinash G.
    Cellamare, Matteo
    Visser, Otto
    de Munck, Linda
    Elferink, Marloes A. G.
    Westenend, Pieter J.
    Wesseling, Jelle
    Broeders, Mireille J. M.
    Kuipers, Ernst J.
    Merkx, Matthias A. W.
    Nagtegaal, Iris D.
    Siesling, Sabine
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [7] Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands Comment
    Dinmohamed, Avinash G.
    Visser, Otto
    Verhoeven, Rob H. A.
    Louwman, Marieke W. J.
    van Nederveen, Francien H.
    Willems, Stefan M.
    Merkx, Matthias A. W.
    Lemmens, Valery E. P. P.
    Nagtegaal, Iris D.
    Siesling, Sabine
    [J]. LANCET ONCOLOGY, 2020, 21 (06) : 750 - 751
  • [8] Effect of the COVID-19 Pandemic on Surgical Breast Cancer Care in the Netherlands: A Multicenter Retrospective Cohort Study
    Filipe, Mando D.
    van Deukeren, Desiree
    Kip, Marijn
    Doeksen, Annemiek
    Pronk, Apollo
    Verheijen, Paul M.
    Heikens, Joost T.
    Witkamp, Arjen J.
    Richir, Milan C.
    [J]. CLINICAL BREAST CANCER, 2020, 20 (06) : 454 - 461
  • [9] COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
    Garassino, Marina Chiara
    Whisenant, Jennifer G.
    Huang, Li-Ching
    Trama, Annalisa
    Torri, Valter
    Agustoni, Francesco
    Baena, Javier
    Banna, Giuseppe
    Berardi, Rossana
    Bettini, Anna Cecilia
    Bria, Emilio
    Brighenti, Matteo
    Cadranel, Jacques
    De Toma, Alessandro
    Chini, Claudio
    Cortellini, Alessio
    Felip, Enriqueta
    Finocchiaro, Giovanna
    Garrido, Pilar
    Genova, Carlo
    Giusti, Raffaele
    Gregorc, Vanesa
    Grossi, Francesco
    Grosso, Federica
    Intagliata, Salvatore
    La Verde, Nicla
    Liu, Stephen, V
    Mazieres, Julien
    Mercadante, Edoardo
    Michielin, Olivier
    Minuti, Gabriele
    Moro-Sibilot, Denis
    Pasello, Giulia
    Passaro, Antonio
    Scotti, Vieri
    Solli, Piergiorgio
    Stroppa, Elisa
    Tiseo, Marcello
    Viscardi, Giuseppe
    Voltolini, Luca
    Wu, Yi-Long
    Zai, Silvia
    Pancaldi, Vera
    Dingemans, Anne-Marie
    Van Meerbeeck, Jan
    Barlesi, Fabrice
    Wakelee, Heather
    Peters, Solange
    Horn, Leora
    [J]. LANCET ONCOLOGY, 2020, 21 (07) : 914 - 922
  • [10] Consequences of COVID-19 for cancer care - a CRUK perspective
    Greenwood, Emma
    Swanton, Charles
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (01) : 3 - 4